An enzymatic immunoassay system for rat HEV





Human cases of Rocahepevirus ratti (HEV-C1) infection are increasingly reported worldwide. Serological tests for HEV-C1 infection are necessary for measuring the clinical burden of HEV-C1 on communities. Currently available commercial hepatitis E serology kits are not very sensitive for HEV-C1 infection and are unable to differentiate between Paslahepevirus balayani genoype 4 (HEV-A4) and Rocahepevirus ratti genotype 1 (HEV-C1) positive patient sera.

In a recent study, the team of Dr. Siddharth Sridhar from the University of Hong Kong developed a parallel IgG enzymatic assay (EIA) system using two virus-like particle peptides (HEV-A4 p239 and HEV-C1 p241). The peptide coating concentrations and serum dilution were optimized by the checkerboard method. Using a panel of confirmed HEV-C1 and HEV-A4 patient sera, cut-offs for individual EIAs and Optical density(OD) HEV-A4 p239/ODHEV-C1 p241 (‘A/C ratio’) were established by Receiver operator characteristic (ROC) curves. Finally, they applied the parallel IgG EIA system to measure HEV-C1 IgG seroprevalence of solid organ transplant (SOT) recipients and immunocompetent patient cohorts. HEV-C1 IgG seropositivity tended to be higher among SOT recipients than individuals who were immunocompetent. The overall measured HEV-C1 seroprevalence in the Hong Kong population was 11/1198 (0.9%).

This parallel IgG EIA system can simultaneously detect HEV antibodies and differentiate between individuals with HEV-A exposure and HEV-C1 exposure and is a valuable tool for investigating epidemiology and risk factors for HEV-C1 infection. The authors look forward to using this assay for wider seroprevalence studies and discovering risk factors for HEV-C1 infection.

This study was published in JHEP Reports (2023 May 15;5(9):100793). Mr. Jianwen Situ serves as the first author, and Dr. Sridhar as the senior author.

Read the full article: DOI: 10.1016/j.jhepr.2023.100793


Link Original Publication





More of this tag...

Diagnostics

Virology

HEV ORF1 protein processing linked to liver fibrosis
Published by -
Hepatitis E virus (HEV) is one of the leading causes of viral hepatitis in humans, with roughly 20 million infections every year and approximately 60,000 HEV-related deaths. Sporadic and cluster cases of hepatitis E disease in industrialized societie

Diagnostics

Virology

Annexin II helps ORF3 sorting into vesicles and quasi-enveloped HEV virions
Published by Xin Yin, Lin Wang
Historically classified as nonenveloped, hepatitis E virus (HEV), an important zoonotic pathogen, has recently been found to exit infected cells as quasi-enveloped HEV (eHEV). These quasi-enveloped virions circulate in the blood and exhibit resistanc






EVENTS

2025-01-18

International Joint Meeting on Viral Infections of the Liver and the Heart (2025)
Day two of this symposium will place a special emphasis on Hepatitis E — a virus that, despite being the most common cause of viral hepatitis, offers a valuable opportunity for further research and understanding. Venue: Cantinerie Berlin Gustav-Meyer-Allee 25 13355 Berlin, Germany. Organisers: Prof. Dr. Jens Kurreck, Dr. rer. nat. Daniel Todt, Prof. Dr. med. Heiner Wedemeyer, More information: Medizinische Hochschule Hannover : International DFG/DZIF Joint Meeting on Viral Infections of the Liver and the Heart (mhh.de)

GHEP offers free membership for your better connection with the hepatitis E community